Why the study?
Does acetylprocainamide therapy cause recurrence of lupus syndrome in patients with previous procainamide-induced lupus syndrome?
Does acetylprocainamide therapy cause recurrence of lupus syndrome in patients with previous procainamide-induced lupus syndrome?
Acetylprocainamide can be used to treat arrhythmias in patients with prior procainamide-induced lupus without typically causing lupus recurrence, supporting the hypothesis that the aromatic amino group in procainamide is responsible for the lupus-inducing effect.
Answers are grounded in this paper and cite their sources.
May support acetylprocainamide in prior procainamide-induced lupus; leaves open prospective confirmation of low recurrence risk.
Acetylprocainamide was used to treat 11 patients with previous procainamide-induced lupus syndrome for their cardiac arrhythmias. Three patients from whom procainamide had been withdrawn and whose lupus was in remission did not have a recurrence during a course of acetylprocainamide therapy of a longer average duration than their prior procainamide therapy. Lupus symptoms subsided during treatment in two patients who had symptoms when acetylprocainamide was started. Drug fever developed in one patient, and another had a mild recurrence of lupus symptoms during high-dose acetylprocainamide therapy that regressed with dosage reduction. All patients had small amounts of circulating procainamide from in-vivo deacetylation of acetylprocainamide. These observations strongly support the hypothesis that the aromatic amino group on procainamide is important for induction of the lupus syndrome and that acetylating this amino group blocks the lupus-inducing effect.
No takes yet. Share an insight, caveat, or question.
Jeffrey Kluger (1981) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: